BRPI0518700A2 - combinaÇÕes antitumorais, contendo um agente inibidor de vegf e 5fu ou um de seus derivados - Google Patents

combinaÇÕes antitumorais, contendo um agente inibidor de vegf e 5fu ou um de seus derivados

Info

Publication number
BRPI0518700A2
BRPI0518700A2 BRPI0518700-1A BRPI0518700A BRPI0518700A2 BR PI0518700 A2 BRPI0518700 A2 BR PI0518700A2 BR PI0518700 A BRPI0518700 A BR PI0518700A BR PI0518700 A2 BRPI0518700 A2 BR PI0518700A2
Authority
BR
Brazil
Prior art keywords
vegf
derivatives
combinations containing
inhibiting agent
antitumor
Prior art date
Application number
BRPI0518700-1A
Other languages
English (en)
Inventor
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Eric Furfine
Jocelyn Holash
Jesse M Cedarbaum
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518700(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0518700A2 publication Critical patent/BRPI0518700A2/pt
Publication of BRPI0518700B1 publication Critical patent/BRPI0518700B1/pt
Publication of BRPI0518700B8 publication Critical patent/BRPI0518700B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINAÇÕES ANTITUMORAIS, CONTENDO UM AGENTE INIBIDOR DE VEGF E 5FU OU UM DE SEUS DERIVADOS. Combinações antitumorais contendo um agente inibidor de VEGF e 5FU ou um de seus derivados. Combinações antitumorais constituídas de inibidor de VEGF as- sociados à 5-fluorouracila ou um derivado de fluoropirimidina terapeutica- mente útil no tratamento das doenças neoplásicas.
BRPI0518700A 2004-12-03 2005-12-02 combinação contendo vegf-trap, 5-fluorouracila e ácido folínico BRPI0518700B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
FR0412870 2004-12-03
PCT/FR2005/003005 WO2006059012A1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives

Publications (3)

Publication Number Publication Date
BRPI0518700A2 true BRPI0518700A2 (pt) 2008-12-02
BRPI0518700B1 BRPI0518700B1 (pt) 2020-02-11
BRPI0518700B8 BRPI0518700B8 (pt) 2021-05-25

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518700A BRPI0518700B8 (pt) 2004-12-03 2005-12-02 combinação contendo vegf-trap, 5-fluorouracila e ácido folínico

Country Status (25)

Country Link
US (3) US20060178305A1 (pt)
EP (1) EP1824504B1 (pt)
JP (1) JP4980236B2 (pt)
KR (1) KR101313404B1 (pt)
CN (1) CN101068564B (pt)
AT (1) ATE426409T1 (pt)
AU (1) AU2005311191C1 (pt)
BR (1) BRPI0518700B8 (pt)
CA (1) CA2586735C (pt)
CY (3) CY1109181T1 (pt)
DE (1) DE602005013568D1 (pt)
DK (1) DK1824504T3 (pt)
ES (1) ES2324233T3 (pt)
FR (3) FR2878749B1 (pt)
HR (1) HRP20090336T1 (pt)
IL (1) IL183481A (pt)
LU (2) LU92202I2 (pt)
ME (1) ME01706B (pt)
MX (1) MX2007006607A (pt)
PL (1) PL1824504T3 (pt)
PT (1) PT1824504E (pt)
RS (1) RS50769B (pt)
RU (1) RU2384344C2 (pt)
SI (1) SI1824504T1 (pt)
WO (1) WO2006059012A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc. anticorpos e conjugados dos mesmos
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
RS50073B (sr) * 1999-06-08 2009-01-22 Regeneron Pharmaceuticals I.N.C., Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
SI1824504T1 (sl) 2009-08-31
DK1824504T3 (da) 2009-07-20
DE602005013568D1 (de) 2009-05-07
CY2013018I1 (el) 2020-05-29
IL183481A0 (en) 2007-09-20
BRPI0518700B1 (pt) 2020-02-11
PL1824504T3 (pl) 2009-08-31
US20130184205A1 (en) 2013-07-18
LU92202I9 (pt) 2019-01-15
RU2007123607A (ru) 2009-01-10
EP1824504B1 (fr) 2009-03-25
US20060178305A1 (en) 2006-08-10
HRP20090336T1 (hr) 2009-07-31
ES2324233T3 (es) 2009-08-03
FR13C0025I1 (fr) 2013-05-24
CA2586735A1 (fr) 2006-06-08
HK1114769A1 (en) 2008-11-14
RS50769B (sr) 2010-08-31
CY1109181T1 (el) 2014-07-02
ME01706B (me) 2010-08-31
CN101068564B (zh) 2010-12-15
KR101313404B1 (ko) 2013-10-01
FR2878749A1 (fr) 2006-06-09
CA2586735C (fr) 2014-08-12
CY2013017I1 (el) 2014-07-02
MX2007006607A (es) 2007-07-25
US20090285841A1 (en) 2009-11-19
LU92203I9 (pt) 2019-01-15
CN101068564A (zh) 2007-11-07
RU2384344C2 (ru) 2010-03-20
AU2005311191B2 (en) 2011-12-08
EP1824504A1 (fr) 2007-08-29
AU2005311191C1 (en) 2015-04-30
WO2006059012A1 (fr) 2006-06-08
IL183481A (en) 2013-09-30
FR2878749B1 (fr) 2007-12-21
BRPI0518700B8 (pt) 2021-05-25
JP2008521866A (ja) 2008-06-26
KR20070091130A (ko) 2007-09-07
JP4980236B2 (ja) 2012-07-18
AU2005311191A1 (en) 2006-06-08
ATE426409T1 (de) 2009-04-15
FR13C0024I1 (fr) 2013-05-24
US8388963B2 (en) 2013-03-05
PT1824504E (pt) 2009-06-25
LU92202I2 (fr) 2013-11-15
LU92203I2 (fr) 2013-11-15

Similar Documents

Publication Publication Date Title
DK1689724T3 (da) Quinazolinonforbindelser som anticancermidler
PL2201840T3 (pl) Inhibitory kinazy tyrozynowej Brutona
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
SG151267A1 (en) Carboline derivatives useful in the inhibition of angiogenesis
ATE496623T1 (de) Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
ECSP055669A (es) Derivados de pirimidinona como agentes terapéuticos contra procesos de remodelación, isquemicos e inflamatorios agudos y cronicos
ATE448232T1 (de) Substituierte heterozyklen
IL183481A0 (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2006041902A3 (en) Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
WO2010040803A3 (en) Kv1.3 channel blocking substances for the treatment of diseases associated with intimal hyperplasia
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
ATE477805T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
ATE509630T1 (de) Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
HUP0203153A2 (hu) Kombinációs kemoterápia
MXPA04005207A (es) Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
NO20053903L (no) Nukleotidlipidesterderivater.
NO20075508L (no) Stannsoporfinpreparater og administrering
GEP20104911B (en) Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues
WO2007012967A3 (en) Combination of voriconazole and fluconazole
UA128071U (uk) Етил-2-(хіназолін-4-іл-аміно)-4,5,6,7-тетрагідро-1-бензотіофен-3-карбоксилат гідрохлорид, що має протипухлинну активність при недрібноклітинному раку легенів людини
UY29237A1 (es) Metodos detratamiento y prevencion
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
HN2003000273A (es) Derivados heterociclicos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: AVENTIS PHARMA SARL (FR)

B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMA SARL (FR)

B25A Requested transfer of rights approved

Owner name: SANOFI MATURE IP (FR)